Common TitleStudy 1249
Official Title A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Phase Phase IIIB
ClinicalTrials.gov NCT02071082
Treatments
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine

Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine
Tradename:GenvoyaOther Names:EVG-COBI-TAF-FTCClass:Single-Tablet RegimensCategories PharmacologyTreatment-ExperiencedSwitch/SimplificationAdverse Effects
Funding
IndustryGilead Sciences
References
- Gallant J, Brunetta J, Crofoot G, et al. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr. 2016;73:294-8.